IP Verse

Pharmaceutical Formulations Of Bruton'S Tyrosine Kinase Inhibtor

Patent No. EP3265084 (titled "Pharmaceutical Formulations Of Bruton'S Tyrosine Kinase Inhibtor") was filed by Pharmacyclics on Mar 2, 2016. The application was issued on Nov 22, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSAug 21, 2024VON KAUFFMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3265084

PHARMACYCLICS
Application Number
EP16759417A
Filing Date
Mar 2, 2016
Status
Granted And Under Opposition
Oct 20, 2023
Publication Date
Nov 22, 2023
External Links
Slate, Register , Google Patents